RT Journal Article
SR Electronic
T1 Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects
JF RMD Open
JO RMD Open
FD EULAR
SP e001637
DO 10.1136/rmdopen-2021-001637
VO 7
IS 2
A1 Josef S Smolen
A1 Roberto Caporali
A1 Thomas Doerner
A1 Bruno Fautrel
A1 Fabrizio Benedetti
A1 Burkhard Pieper
A1 Minjun Jang
YR 2021
UL http://rmdopen.bmj.com/content/7/2/e001637.abstract
AB Early diagnosis and treatment of rheumatoid arthritis (RA) are of critical importance to halt the progression of the disease. Optimal use of advanced imaging techniques or biomarkers may facilitate early diagnosis of RA. Even though many disease-modifying anti-rheumatic drugs (DMARDs) are available for RA treatment, biological DMARDs (bDMARDs) offer expanding therapeutic options and good outcomes in patients with RA who do not have a sufficient response to conventional synthetic DMARDs. However, high costs of bDMARDs have limited patient access to optimised disease management and increased the cost burden for healthcare systems. The advent of biosimilars led to significant cost savings driven by price competition among the reference products, which could be beneficial for healthcare systems. Healthcare provider (HCP)–patient communication and informed shared decision-making are crucial to prevent the occurrence of a nocebo effect, which results from negative perceptions that patients may have and could lead to less effective outcomes. Research has demonstrated that effective communication between HCPs and patients utilising positive framing can improve acceptance by patients to be initiated on or switched to a biosimilar and can help to integrate biosimilars into routine clinical practice to maximise benefits for patients with RA.